[{"address1": "117, Avenue de Luminy", "address2": "BP 30191", "city": "Marseille", "zip": "13009", "country": "France", "phone": "33 4 30 30 30 30", "fax": "33 4 30 30 30 00", "website": "https://www.innate-pharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory s\u00e9zary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.", "fullTimeEmployees": 179, "companyOfficers": [{"maxAge": 1, "name": "Dr. Herve  Brailly Ph.D.", "age": 62, "title": "Co-Founder, Interim CEO & Chairman of Executive Board", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Yannis  Morel Ph.D.", "age": 50, "title": "Executive VP, COO & Member of Executive Board", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 402284, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Fran\u00e7ois  Romagn\u00e9 Ph.D.", "age": 59, "title": "Founder", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric  Vivier D.V.M., M.B.A., Ph.D.", "age": 59, "title": "Founder, Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Bonneville Ph.D.", "age": 63, "title": "Founder", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean Jacques Fourni\u00e9 Ph.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alessandro  Moretta M.D., Ph.D.", "title": "Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederic  Lombard M.B.A.", "age": 48, "title": "Senior VP & CFO", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sonia  Quaratino M.D., Ph.D.", "age": 56, "title": "Executive VP, Chief Medical Officer & Member of Executive Board", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Arvind  Sood", "title": "Executive VP, President of US Operations & Member of Executive Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 1, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.13, "dayLow": 2.2, "dayHigh": 2.2, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.13, "regularMarketDayLow": 2.2, "regularMarketDayHigh": 2.2, "beta": 0.789, "volume": 2000, "regularMarketVolume": 2000, "averageVolume": 161, "averageVolume10days": 100, "averageDailyVolume10Day": 100, "bid": 1.85, "ask": 2.82, "bidSize": 40000, "askSize": 40000, "marketCap": 187240928, "fiftyTwoWeekLow": 1.93, "fiftyTwoWeekHigh": 3.0, "priceToSalesTrailing12Months": 3.0376036, "fiftyDayAverage": 2.1056, "twoHundredDayAverage": 2.461365, "currency": "USD", "enterpriseValue": 133405976, "profitMargins": -0.12281, "floatShares": 31524168, "sharesOutstanding": 80950800, "heldPercentInsiders": 0.25032, "heldPercentInstitutions": 0.10074, "bookValue": 0.642, "priceToBook": 3.5825543, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -7570000, "trailingEps": -0.1, "enterpriseToRevenue": 2.164, "enterpriseToEbitda": -17.604, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "IPHYF", "underlyingSymbol": "IPHYF", "shortName": "INNATE PHARMA", "longName": "Innate Pharma S.A.", "firstTradeDateEpochUtc": 1433856600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "08e96959-da62-3baa-9967-ba371df08448", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.3, "recommendationKey": "none", "totalCash": 92456000, "totalCashPerShare": 1.143, "ebitda": -7578000, "totalDebt": 39893000, "quickRatio": 3.505, "currentRatio": 3.734, "totalRevenue": 61641000, "debtToEquity": 76.864, "revenuePerShare": 0.766, "returnOnAssets": -0.04039, "returnOnEquity": -0.14276, "freeCashflow": -27067124, "operatingCashflow": -32558000, "revenueGrowth": 0.774, "grossMargins": 0.09116, "ebitdaMargins": -0.12294, "operatingMargins": -0.57221, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]